US approves joint damage data for Cosentyx
US regulators have approved new evidence showing that Novartis’ Cosentyx significantly slows progression of joint structural damage in patients with active psoriatic arthritis (PsA).
Read More
Tag: secukinumab
Novartis’ Cosentyx beats J&J’s Stelara in psoriasis trial
Novartis has released trial data showing that Cosentyx was “significantly more effective” than Johnson & Johnson’s rival biologic Stelara in achieving clear skin in patients with psoriasis.
Read More
Novartis’ Cosentyx shown to inhibit joint damage in PsA
Novartis has presented new data showing that its biologic Cosentyx reduced signs and symptoms of psoriatic arthritis (PsA) while inhibiting progression of joint structural damage.
Read More
NICE nod for psoriatic arthritis drugs Cimzia and Cosentyx
Cost regulators for the NHS in England and Wales are recommending UCB’s Cimzia and Novartis’ Cosentyx as treatment options for adults with active psoriatic arthritis.
Read More
NICE nod for Novartis’ Cosentyx in PsA
The National Institute for Health and Care Excellence has published a positive Final Appraisal Determination which backs NHS use of Novartis’ Cosentyx in adults with active and progressive psoriatic arthritis.
Read More
Study shows Novartis’ Cosentyx may modify course of psoriasis
Novartis has unveiled trial results which it says show that Cosentyx is the first and only IL-17A inhibitor to potentially modify the course of psoriasis.
Read More
NICE backs use of UCB’s Cimzia, Novartis’ Cosentyx for psoriatic arthritis
Cost regulators for the NHS in England and Wales are backing UCB’s Cimzia and Novartis’ Cosentyx as treatment options for adults with active psoriatic arthritis.
Read More
Final NICE yes for Novartis’ Cosentyx in ankylosing spondylitis
Guidelines from the National Institute for Health and Care Excellence recommend Novartis’ Cosentyx for treating active ankylosing spondylitis that has not responded well enough to conventional therapy.
Read More
NICE supports Novartis’ Cosentyx for ankylosing spondylitis
National Health Service use of Novartis’ Cosentyx to treat active ankylosing spondylitis is being endorsed by the National Institute for Health and Care Excellence.
Read More
Novartis plans head-to-head trial for Cosentyx and Humira
Novartis and Sandoz are to present new analyses indicating that their biologic Cosentyx could lead to higher responses than AbbVie’s anti-inflammatory super-blockbuster Humira in improving the signs and symptoms of ankylosing spondylitis and psoriatic arthritis.
Read More
- Liverpool and McMaster University announce £300,000 strategic research partnership
- Study finds link between malaria parasites developing antimalarial drug resistance
- Researchers develop ‘digital twin’ heart models to better monitor PAH NHS patients
- Closed Loop and Pharmanovia investigate precision medicine combination in hypertension
- US study reveals interferon combinations cause lupus symptoms and affect treatment
